Pristimerin Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review

References

• Tang WH, Bai ST, Tong L, et al. Chemical constituents from Celastrus aculeatus merr. Biochem Syst Ecol. 2014;54:78–82. doi:10.1016/j.bse.2014.01.001
   Web of Science ®Google Scholar
• Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352–364. doi:10.1002/path.3022
   PubMed Web of Science ®Google Scholar
• Massagué J. G1 cell-cycle control and cancer. nature. 2004;432(7015):298–306. doi:10.1038/nature03094
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115. doi:10.1038/nrc.2016.138
   PubMed Web of Science ®Google Scholar
• Zhao Q, Liu Y, Zhong J, et al. Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo. Cell Death Discovery. 2019;5:125. doi:10.1038/s41420-019-0208-0
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren Z, Li X, et al. Pristimerin induces autophagy-mediated cell death in K562 cells through the ROS/JNK signaling pathway. Chem Biodivers. 2019;16(8):e1900325. doi:10.1002/cbdv.201900325
   PubMed Web of Science ®Google Scholar
• Sun JM, Xu HT, Zhao L, et al. Induction of cell-cycle arrest and apoptosis in human cholangiocarcinoma cells by pristimerin. J Cell Biochem. 2019;120(7):12002–12009. doi:10.1002/jcb.28485
   PubMed Web of Science ®Google Scholar
• Yousef BA, Hassan HM, Guerram M, et al. Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells. Biomed & Pharmacotherap. 2016;79:112–119. doi:10.1016/j.biopha.2016.02.003
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, McAllister SS, et al. CDK4/6 inhibition in cancer: Beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911–925. doi:10.1016/j.tcb.2018.07.002
   PubMed Web of Science ®Google Scholar
• Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 2003;13(2):65–70. doi:10.1016/s0962-8924(02)00043-0
   PubMed Web of Science ®Google Scholar
• Georgakilas AG, Martin OA, Bonner WM. p21: A two-faced genome guardian. Trends mol med. 2017;23(4):310–319. doi:10.1016/j7molmed.2017.02.001
   PubMed Web of Science ®Google Scholar
• Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ. 2018;25(1):114–132. doi:10.1038/cdd.2017.172
   PubMed Web of Science ®Google Scholar
• Wu H, Li L, Ai Z, et al. Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G(1) phase arrest and MAPK/Erk1/2 and Akt signaling inhibition. Oncol Lett. 2019;17(3):3017–3025. doi:10.3892/ol.2019.9903
   PubMed Web of Science ®Google Scholar
• Liu YB, Gao X, Deeb D, et al. Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin. Int j Oncol. 2014;45(4):1735–1741. doi:10.3892/ijo.2014.2561
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou Y, Zhou H, et al. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PLoS One. 2012;7(8):e43826. doi:10.1371/journal.pone.0043826
   PubMed Web of Science ®Google Scholar
• Eum DY, Byun JY, Yoon CH, et al. Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species- mediated mitochondrial dysfunction. Anti-Cancer Drugs. 2011;22(8):763–773. doi:10.1097/CAD.0b013e328347181a
   PubMed Web of Science ®Google Scholar
• Byun JY, Kim MJ, Eum DY, et al. Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol. 2009;76(4):734–744. doi:10.1124/mol.109.056259
   PubMed Web of Science ®Google Scholar
• Costa PM, Ferreira PM, Bolzani Vda S, et al. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxi vitro. 2008;22(4):854–863. doi:10.1016/j.tiv.2008.01.003
   PubMed Web of Science ®Google Scholar
• Wu CC, Chan ML, Chen WY, et al. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther. 2005;4(8):1277–1285. doi:10.1158/1535-7163.Mct-05-0027
   PubMed Web of Science ®Google Scholar
• Deeb D, Gao X, Liu YB, et al. Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro- survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2. Int j Oncol. 2014;44(5):1707–1715. doi:10.3892/ijo.2014.2325
   PubMed Web of Science ®Google Scholar
• Yang H, Landis-Piwowar KR, Lu D, et al. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem. 2008;103(1):234–244. doi:10.1002/jcb.21399
   PubMed Web of Science ®Google Scholar
• Liu YB, Gao X, Deeb D, et al. Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent Ubiquitin- proteasomal Degradation Pathway. J Carcinogenesis Mutagenesis. 2013;(6):005. doi:10.4172/2157-2518.S6-005
   PubMedGoogle Scholar
• Gao X, Liu Y, Deeb D, et al. Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/ mTOR signaling. j Experim Therap. 2014;10(4):275–283.
   PubMedGoogle Scholar
• Hayashi D, Shirai T, Terauchi R, et al. Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis. Oncology Let. 2020;19(4):2963–2970. doi:10.3892/ol.2020.11405
   PubMed Web of Science ®Google Scholar
• Zhao Q, Bi Y, Guo J, et al. Effect of pristimerin on apoptosis through activation of ROS/ endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer. Phytomed. 2021;80:153399. doi:10.1016/j.phymed.2020.153399
   PubMed Web of Science ®Google Scholar
• Cevatemre B, Erkısa M, Aztopal N, et al. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autophagy in breast cancer. Pharmacol Res. 2018;129:500–514. doi:10.1016/j.phrs.2017.11.027
   PubMed Web of Science ®Google Scholar
• Lee Y, Na J, Lee MS, et al. Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation. Mole med rep. 2018;18(5):4281–4288. doi:10.3892/mmr.2018.9488
   PubMed Web of Science ®Google Scholar
• Huang P, Sun LY, Zhang YQ. A hopeful natural product, pristimerin, induces apoptosis, cell cycle arrest, and autophagy in esophageal cancer cells. Anal Cell Patho. 2019;2019:6127169. doi:10.1155/2019/6127169
   Web of Science ®Google Scholar
• Jiang H, Xie Y, Lu J, et al. Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD/ASC stability via selective autophagy to alleviate tendinopathy. autophagy. 2023:1–18. doi:10.1080/15548627.2023.2249392
   Web of Science ®Google Scholar
• Zhang Y, Wang J, Hui B, et al. Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a/Akt/GSK3β signaling pathway and suppressing autophagy in lung cancer cells. IntJ Mol Med. 2019;43(3):1382–1394. doi:10.3892/ijmm.2019.4057
   PubMed Web of Science ®Google Scholar
• Mu XM, Shi W, Sun LX, et al. Pristimerin inhibits breast cancer cell migration by up- regulating regulator of G protein signaling 4 expression. Asian Pacific j Can Preven. 2012;13(4):1097–1104. doi:10.7314/apjcp.2012.13.4.1097
   PubMedGoogle Scholar
• Liu S, Dong Y, Wang Y, et al. Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial- mesenchymal transition via downregulation of integrin β3. Biomed J. 2021;44(6 Suppl 1):S84–s92. doi:10.1016/j.bj.2020.07.004
   PubMed Web of Science ®Google Scholar
• Lee JS, Yoon IS, Lee MS, et al. Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells. Biol Pharm Bull. 2013;36(2):316–325. doi:10.1248/bpb.b12-00685
   PubMed Web of Science ®Google Scholar
• Zuo J, Guo Y, Peng X, et al. Inhibitory action of pristimerin on hypoxia-mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells. Oncol Rep. 2015;33(3):1388–1394. doi:10.3892/or.2015.3708
   PubMed Web of Science ®Google Scholar
• Huang S, He P, Peng X, et al. Pristimerin inhibits prostate cancer bone metastasis by targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs. Cell Physiol Biochem. 2015;37(1):253–268. doi:10.1159/000430350
   PubMedGoogle Scholar
• Lee SO, Kim JS, Lee MS, et al. Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells. BMC canc. 2016;16(1):701. doi:10.1186/s12885-016-2730-2
   PubMedGoogle Scholar
• Lei X, Zhong Y, Huang L, et al. Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer. Cell Death Dis. 2020;11(4):232. doi:10.1038/s41419-020-2425-0
   PubMed Web of Science ®Google Scholar
• Lu Z, Jin Y, Chen C, et al. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 2010;9:112. doi:10.1186/1476-4598-9-112
   PubMed Web of Science ®Google Scholar
• Tu Y, Tan F, Zhou J, et al. Pristimerin targeting NF-κB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells. Cell Biochem Funct. 2018;36(4):228–240. doi:10.1002/cbf.3335
   PubMed Web of Science ®Google Scholar
• Yousef BA, Hassan HM, Zhang LY, et al. Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-кB signaling pathway in colorectal cancer cells. Phytomedicine. 2018;40:140–147. doi:10.1016/j.phymed.2018.01.008
   PubMed Web of Science ®Google Scholar
• Li Z, Hu C, Zhen Y, et al. Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p. Biosci Rep. 2019 39(5) doi:10.1042/bsr20182389
   Google Scholar
• Huang D, Su L, He C, et al. Pristimerin alleviates cigarette smoke-induced inflammation in chronic obstructive pulmonary disease via inhibiting NF-κB pathway. Biochi Et Biologie Cellulai. 2022;100(3):223–235. doi:10.1139/bcb-2021-0251
   PubMedGoogle Scholar
• Mu X, Shi W, Sun L, et al. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules. 2012;17(6):6854–6868. doi:10.3390/molecules17066854
   PubMed Web of Science ®Google Scholar
• Mori Y, Shirai T, Terauchi R, et al. Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo. Onco Targets Ther. 2017;10:5703–5710. doi:10.2147/ott.S150071
   PubMed Web of Science ®Google Scholar
• Yan F, Liao R, Silva M, et al. Pristimerin-induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway. J Cell & Mol Med. 2020;24(11):6208–6219. doi:10.1111/jcmm.15249
   PubMed Web of Science ®Google Scholar
• Xue W, Li Y, Zhang M. Pristimerin inhibits neuronal inflammation and protects cognitive function in mice with sepsis-induced brain injuries by regulating PI3K/Akt signalling. Pharm Biol. 2021;59(1):1351–1358. doi:10.1080/13880209.2021.1981399
   PubMed Web of Science ®Google Scholar
• Al-Tamimi M, Khan AQ, Anver R, et al. Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways. Biomed Pharmacoth. 2022;156:113950. doi:10.1016/j.biopha.2022.113950
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang C, Lu B, et al. Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK. Cancer Lett. 2016;374(1):136–148. doi:10.1016/j.canlet.2016.01.055
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhang W, Yan YY, et al. Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction. j BUON. 2013;18(2):877–887.
   Web of Science ®Google Scholar
• Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discovery. 2015;5(5):475–487. doi:10.1158/2159-8290.Cd-15-0011
   PubMed Web of Science ®Google Scholar
• Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13(15):1899–1911. doi:10.1101/gad.13.15.1899
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053–1058. doi:10.1126/science.288.5468.1053
   PubMed Web of Science ®Google Scholar
• Ravanan P, Srikumar IF, Talwar P. Autophagy: the spotlight for cellular stress responses. Life Sci. 2017;188:53–67. doi:10.1016/j.lfs.2017.08.029
   PubMed Web of Science ®Google Scholar
• Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annu Rev Biophys. 2013;42:3017–3025. doi:10.3892/ol.2019.9903
   Web of Science ®Google Scholar
• Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-κB: a Blossoming of Relevance to Human Pathobiology. cell. 2017;168(1–2):37–57. doi:10.1016/j.cell.2016.12.012
   PubMed Web of Science ®Google Scholar
• Sacks D, Baxter B, Campbell BCV, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. int j strok. 2018;13(6):612–632. doi:10.1177/1747493018778713
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203. doi:10.1038/nrm3290
   PubMed Web of Science ®Google Scholar
• Fayard E, Xue G, Parcellier A, et al. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curren Topic Microbiol Immuno. 2010;346:31–56. doi:10.1007/82_2010_58
   PubMed Web of Science ®Google Scholar
• Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Bio. 2020;21(4):183–203. doi:10.1038/s41580-019-0199-y
   PubMed Web of Science ®Google Scholar
• Camillo P, Paglino C, Mosca A, et al. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4(4):64. doi:10.3389/fonc.2014.00064
   PubMedGoogle Scholar
• Lorusso PM. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. Am Soc Clin Oncol. 2016;34:3803–3815. doi:10.1200/jco.2014.59.0018
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. bioch et biophysica acta. 2010;1802(4):396–405. doi:10.1016/j.bbadis.2009.12.009
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu WZ, Liu T, et al. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. j Receptor Sig Trans Res. 2015;35(6):600–604. doi:10.3109/10799893.2015.1030412
   PubMed Web of Science ®Google Scholar
• Liou GY, Storz P. Reactive oxygen species in cancer. Free Radical Research. 2010;44(5):479–496. doi:10.3109/10715761003667554
   PubMed Web of Science ®Google Scholar
• Zhao Q, Bi Y, Zhong J, et al. Pristimerin suppresses colorectal cancer by inhibiting inflammatory responses and Wnt/β-catenin signaling. Toxicol Appl Pharm. 2020;386:114813. doi:10.1016/j.taap.2019.114813
   PubMed Web of Science ®Google Scholar
• Li J, Guo Q, Lei X, et al. Pristimerin induces apoptosis and inhibits proliferation, migration in H1299 Lung Cancer Cells. J Canc. 2020;11(21):6348–6355. doi:10.7150/jca.44431
   Web of Science ®Google Scholar
• Xie X, Xie S, Xie C, et al. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways. J Cell & Mol Med. 2019;23(11):7545–7553. doi:10.1111/jcmm.14623
   PubMed Web of Science ®Google Scholar
• Bi J, Areecheewakul S, Li Y, et al. MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. Gynecologic Oncol. 2019;155(2):349–358. doi:10.1016/j.ygyno.2019.08.014
   PubMed Web of Science ®Google Scholar
• Xie G, Yu X, Liang H, et al. Pristimerin overcomes Adriamycin resistance in breast cancer cells through suppressing Akt signaling. Oncol Lett. 2016;11(5):3111–3116. doi:10.3892/ol.2016.4335
   PubMed Web of Science ®Google Scholar
• Chen XT, Cheng C, Sheidai T, et al.The mechanisms of pristimerin inducing human lung cancer conditionally reprogrammed cell death via Notch. signaling. 2019;39(20):2025–2030. doi:10.13286/j.cnki.chinhosppharmacyj.2019.20.02
   Google Scholar
• Tang Y, Lei Y, Huang S, et al. Pristimerin Exacerbates Cellular Injury in Conditionally Reprogrammed Patient-Derived Lung Adenocarcinoma Cells by Aggravating Mitochondrial Impairment and Endoplasmic Reticulum Stress through EphB4/CDC42/N-WASP Signaling. Oxid Med Cell Longev. 2020;2020:7409853. doi:10.1155/2020/7409853
   PubMed Web of Science ®Google Scholar
• Liu YB, Gao X, Deeb D, et al. Role of telomerase in anticancer activity of pristimerin in prostate cancer cells. j Experimental Therap. 2015;11(1):41–49.
   PubMedGoogle Scholar
• Deeb D, Gao X, Liu Y, et al. Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells. Oncol Rep. 2015;34(1):518–524. doi:10.3892/or.2015.3989
   PubMed Web of Science ®Google Scholar
• Tian M, Peng S, Wang S, et al. Pristimerin reduces dextran sulfate sodium-induced colitis in mice by inhibiting microRNA-155. Int Immunopharmacol. 2021;94:107491. doi:10.1016/j.intimp.2021.107491
   PubMed Web of Science ®Google Scholar
• Tong L, Nanjundaiah SM, Venkatesha SH, et al. Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage. Clinical Immunology. 2014;155(2):220–230. doi:10.1016/j.clim.2014.09.014
   PubMed Web of Science ®Google Scholar
• Liang J, Yuan S, Wang X, et al. Attenuation of pristimerin on TNF-α-induced endothelial inflammation. Int Immunopharmacol. 2020;82:106326. doi:10.1016/j.intimp.2020.106326
   PubMed Web of Science ®Google Scholar
• Jia H, Liu T, Yang Q, et al. Tumor-Derived PD-L1(+) Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment. Bioconjugate Chem. 2023. doi:10.1021/acs.bioconjchem.3c00129
   Web of Science ®Google Scholar
• Dos Santos VA, Leite KM, da Costa Siqueira M, et al. Antiprotozoal activity of quinonemethide triterpenes from Maytenus ilicifolia (Celastraceae). Molecules. Basel, Switzerland 2013;18(1):1053–1062. doi:10.3390/molecules18011053
   PubMed Web of Science ®Google Scholar
• López MR, de León L, Moujir L, de León L. Antibacterial Properties of Phenolic Triterpenoids against Staphylococcus epidermidis. Planta med. 2011;77(7):726–729. doi:10.1055/s-0030-1250500
   PubMed Web of Science ®Google Scholar
• Nizer WSDC, Ferraz AC, Moraes Td FS, et al. Pristimerin isolated from Salacia crassifolia (Mart. Ex. Schult.) G.Don. (Celastraceae) roots as a potential antibacterial agent against Staphylococcus aureus. J Ethnopharmacol. 2021;266. doi:10.1016/j.jep.2020.113423
   PubMed Web of Science ®Google Scholar
• Murayama T, Eizuru Y, Yamada R, et al. Anticytomegalovirus activity of pristimerin, a triterpenoid quinone methide isolated from Maytenus heterophylla (Eckl. & Zeyh.). Antiviral Chem Chemother. 2007;18(3):133–139. doi:10.1177/095632020701800303
   PubMedGoogle Scholar
• Sun P, Yang Q, Wang Y, et al. Pristimerin inhibits osteoclast differentiation and bone resorption in vitro and prevents ovariectomy-induced bone loss in vivo. Drug Des Devel Ther. 2020;14:4189–4203. doi:10.2147/DDDT.S275128
   PubMed Web of Science ®Google Scholar
• Li X, Lin X, Wu Z, et al. Pristimerin protects against OVX-mediated bone loss by attenuating osteoclast formation and activity via inhibition of RANKL- mediated activation of NF-κB and ERK signaling pathways. Dove Press. 2021. doi:10.2147/DDDT.S283694
   Google Scholar
• Qi D, Liu H, Sun X, et al. Pristimerin suppresses RANKL-induced osteoclastogenesis and ameliorates ovariectomy-induced bone loss. Front Pharmacol. 2021;11:621110. doi:10.3389/fphar.2020.621110
   PubMed Web of Science ®Google Scholar
• Xu W, Zhu X, Chen C, et al. Beneficial effect of pristimerin against the development of osteoporosis in ovariectomy-induced osteoporosis rats by the RANKL/TRAF6/NF-κB pathway. Arch Med Sci. 2019. doi:10.5114/aoms.2019.86816
   Google Scholar
• El-Agamy DS, El-Harbi KM, Khoshhal S, et al. Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways. Cancer Manage Res. 2019;11:47–61. doi:10.2147/cmar.S186696
   PubMed Web of Science ®Google Scholar
• Lu Y, Zeng Z, Bao X, et al. Pristimerin protects against pathological cardiac hypertrophy through improvement of PPARα pathway. Toxicol Appl Pharmacol. 2023. 473. 116572. doi:10.1016/j.taap.2023.116572
   PubMed Web of Science ®Google Scholar
• Al-Romaiyan A, Masocha W. Pristimerin, a triterpene that inhibits monoacylglycerol lipase activity, prevents the development of paclitaxel-induced allodynia in mice. Front Pharmacol. 2022;13:944502. doi:10.3389/fphar.2022.944502
   PubMed Web of Science ®Google Scholar
• Shu C, Yu X, Cheng S, et al. Pristimerin suppresses trophoblast cell epithelial-mesenchymal Transition via miR-542-5p/EGFR Axis. Drug Des Devel Ther. 2020. doi:10.2147/DDDT.S274595
   Web of Science ®Google Scholar
• Rehfeld A, Marcus Pedersen C. Lupeol and pristimerin do not inhibit activation of the human sperm CatSper Ca(2+)-channel. f1000Res. 2022;11:222. doi:10.12688/f1000research.109279.2
   PubMedGoogle Scholar